GSK plc
13F holdings for Q2 2026 · London, X0 · filed August 13, 2026
GSK plc reported $582M in 13F securities across 12 holdings for Q2 2026, in a Form 13F filed August 13, 2026. The largest positions were Crispr Therapeutics AG (30.2%), Wave Life Sciences LTD SHS (18.2%), VIR (15.0%). Reported value rose 0.7% from the quarter before.
- 13F value Q2 2026
- $582M
- Holdings
- 12
- Change vs prior quarter
- +0.7%
- Rank by 13F value
- #3,542
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| Crispr Therapeutics AG | $176M | 30.2% | 3,220,627 | 0% | Unchanged |
| Wave Life Sciences LTD SHS | $106M | 18.2% | 18,245,691 | 0% | Unchanged |
| VIR Vir Biotechnology Inc. | $87.1M | 15.0% | 8,550,954 | 0% | Unchanged |
| BNTX BioNTech SE | $82.8M | 14.2% | 889,824 | 0% | Unchanged |
| IDYA IDEAYA Biosciences Inc. | $49.7M | 8.5% | 1,333,333 | 0% | Unchanged |
| CYTK Cytokinetics Incorporated | $29.0M | 5.0% | 340,434 | 0% | Unchanged |
| LYEL Lyell Immunopharma Inc. | $21.3M | 3.7% | 1,512,659 | 0% | Unchanged |
| NKTX Nkarta Inc. | $8.9M | 1.5% | 3,150,732 | 0% | Unchanged |
| FULC Fulcrum Therapeutics Inc. | $6.5M | 1.1% | 1,785,714 | 0% | Unchanged |
| BCYC Bicycle Therapeutics plc | $6.5M | 1.1% | 1,529,561 | 0% | Unchanged |
| CVRX CVRx Inc. | $5.2M | 0.9% | 1,007,583 | 0% | Unchanged |
| RGNX REGENXBIO Inc. | $3.3M | 0.6% | 271,456 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $582M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
None this quarter.
Biggest sells in Q2 2026
None this quarter.
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 0 added, 0 trimmed, 0 sold out.
Sector mix
- Health Care51.6%
- Not listed with us48.4%
13F value by quarter
Schedule 13D and 13G filings by GSK plc
Stakes above 5% of a company, filed within days rather than once a quarter.
- 2025-08-13CVAC SCHEDULE 13D filed by CureVac N.V.Schedule 13D
Questions about GSK plc
- What does GSK plc own?
- In its Form 13F for Q2 2026, GSK plc reported 12 holdings worth $582M. The five largest were Crispr Therapeutics AG, Wave Life Sciences LTD SHS, VIR, BNTX, IDYA.
- What did GSK plc buy and sell in Q2 2026?
- GSK plc opened 0 new positions, added to 0, trimmed 0 and sold out of 0 compared with the quarter before.
- When did GSK plc file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 13, 2026.
From Form 13F filed by GSK plc (SEC CIK 0001131399) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds